183 related articles for article (PubMed ID: 1142508)
1. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate.
Eisen M; Napp HE; Vock R
J Urol; 1975 Jul; 114(1):93-7. PubMed ID: 1142508
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of platelet aggregation under estrogen-treatment in patients with carcinoma of the prostate (author's transl)].
Eisen M; Napp HE; Vock R
Urologe A; 1975 May; 14(3):132-6. PubMed ID: 1154559
[TBL] [Abstract][Full Text] [Related]
3. Influence of treatment with diethylstilbestrol for carcinoma of prostate on platelet aggregation and plasma lipoproteins.
Agardh CD; Rasmussen F; Nilsson-Ehle P; Gustafson A
Urology; 1986 Dec; 28(6):469-71. PubMed ID: 3787919
[TBL] [Abstract][Full Text] [Related]
4. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of thrombocyte aggregation and thromboxane B2 synthesis by diethylstilbestrol.
Subbiah MT; Gallon L; Yunker R
Pharmacology; 1980; 21(6):396-9. PubMed ID: 7220591
[TBL] [Abstract][Full Text] [Related]
6. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma.
Agardh CD; Nilsson-Ehle P; Lundgren R; Gustafson A
J Urol; 1984 Nov; 132(5):1021-4. PubMed ID: 6492270
[TBL] [Abstract][Full Text] [Related]
7. Progressive enlargement of prostatic nodule after castration.
Meares Em J
JAMA; 1976 Dec; 236(23):2669. PubMed ID: 12277522
[TBL] [Abstract][Full Text] [Related]
8. The effects on platelet aggregation of oral prostaglandin E2 used for the induction of labour.
Myatt L; Elder MG
Br J Obstet Gynaecol; 1975 Jun; 82(6):449-52. PubMed ID: 1138835
[TBL] [Abstract][Full Text] [Related]
9. Treatment of prostatic carcinoma with various types of estrogen derivatives.
Jönsson G; Olsson AM; Luttrop W; Cekan Z; Purvis K; Diczfalusy E
Vitam Horm; 1975; 33():351-76. PubMed ID: 1229063
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of thrombocyte aggregation inhibitors during massive-dose estrogen therapy].
Heinz A; Meyer WW; Hallwachs O
Urologe A; 1984 May; 23(3):178-80. PubMed ID: 6377650
[TBL] [Abstract][Full Text] [Related]
11. Role of surface negative charge in platelet function related to the hyperreactive state in estrogen-treated prostatic carcinoma.
Jung SM; Kinoshita K; Tanoue K; Isohisa I; Yamazaki H
Thromb Haemost; 1982 Jun; 47(3):203-9. PubMed ID: 6180496
[TBL] [Abstract][Full Text] [Related]
12. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
Lundgren R; Nordle O; Josefsson K
J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
[TBL] [Abstract][Full Text] [Related]
13. The choice of estrogen preparations in the treatment of prostatic cancer.
Morales A; Pujari B
Can Med Assoc J; 1975 Nov; 113(9):865-7. PubMed ID: 1182631
[TBL] [Abstract][Full Text] [Related]
14. [Changes in parameters of the coagulation and fibrinolysis system of the blood in patients with prostate cancer in the framework of estrogen therapy].
Gembitskiĭ EV; Begunov AB
Klin Med (Mosk); 1994; 72(2):30-2. PubMed ID: 8015238
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
Carlström K; Stege R
Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
[TBL] [Abstract][Full Text] [Related]
16. Disseminated intravascular coagulation induced by progesterone in the pregnant rat. Prevention by estogens.
Stamler FW
Am J Pathol; 1977 Mar; 86(3):603-22. PubMed ID: 65916
[TBL] [Abstract][Full Text] [Related]
17. [Clinical studies on endocrine therapy of prostatic carcinoma (2): Prognosis of patients with prostatic carcinoma given endocrine therapy, and analyses of causes of death and side effects of endocrine therapy].
Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
Hinyokika Kiyo; 1990 Mar; 36(3):285-93. PubMed ID: 2191570
[TBL] [Abstract][Full Text] [Related]
18. High-dose diethylstilbestrol diphosphate therapy of prostatic cancer after failure of standard doses of estrogens.
Band PR; Banerjee TK; Patwardhan VC; Eid TC
Can Med Assoc J; 1973 Oct; 109(8):697-9. PubMed ID: 4746128
[TBL] [Abstract][Full Text] [Related]
19. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen.
Henriksson P; Carlström K; Pousette A; Gunnarsson PO; Johansson CJ; Eriksson B; Altersgård-Brorsson AK; Nordle O; Stege R
Prostate; 1999 Jul; 40(2):76-82. PubMed ID: 10386467
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T
Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
